Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) Invested Capital (2016 - 2025)

Historic Invested Capital for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $200.6 million.

  • Altimmune's Invested Capital rose 5040.15% to $200.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $200.6 million, marking a year-over-year increase of 5040.15%. This contributed to the annual value of $123.5 million for FY2024, which is 3636.86% down from last year.
  • Altimmune's Invested Capital amounted to $200.6 million in Q3 2025, which was up 5040.15% from $176.4 million recorded in Q2 2025.
  • In the past 5 years, Altimmune's Invested Capital registered a high of $246.4 million during Q1 2021, and its lowest value of $123.5 million during Q4 2024.
  • In the last 5 years, Altimmune's Invested Capital had a median value of $185.3 million in 2022 and averaged $182.0 million.
  • Per our database at Business Quant, Altimmune's Invested Capital skyrocketed by 48820.26% in 2021 and then crashed by 3636.86% in 2024.
  • Quarter analysis of 5 years shows Altimmune's Invested Capital stood at $205.2 million in 2021, then dropped by 9.71% to $185.3 million in 2022, then rose by 4.75% to $194.1 million in 2023, then tumbled by 36.37% to $123.5 million in 2024, then skyrocketed by 62.42% to $200.6 million in 2025.
  • Its last three reported values are $200.6 million in Q3 2025, $176.4 million for Q2 2025, and $142.2 million during Q1 2025.